PT4045038T - Novas formulações de 4-cloro-n-[2-[(4-clorofenil)metil]-3-oxo-1,2,4-tiadiazol-5-il]benzamida - Google Patents

Novas formulações de 4-cloro-n-[2-[(4-clorofenil)metil]-3-oxo-1,2,4-tiadiazol-5-il]benzamida

Info

Publication number
PT4045038T
PT4045038T PT207997958T PT20799795T PT4045038T PT 4045038 T PT4045038 T PT 4045038T PT 207997958 T PT207997958 T PT 207997958T PT 20799795 T PT20799795 T PT 20799795T PT 4045038 T PT4045038 T PT 4045038T
Authority
PT
Portugal
Prior art keywords
thiadiazole
benzamide
chlorophenyl
oxo
chloro
Prior art date
Application number
PT207997958T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Betagenon Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betagenon Ab filed Critical Betagenon Ab
Publication of PT4045038T publication Critical patent/PT4045038T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
PT207997958T 2019-10-18 2020-10-16 Novas formulações de 4-cloro-n-[2-[(4-clorofenil)metil]-3-oxo-1,2,4-tiadiazol-5-il]benzamida PT4045038T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201915094A GB201915094D0 (en) 2019-10-18 2019-10-18 New formulations

Publications (1)

Publication Number Publication Date
PT4045038T true PT4045038T (pt) 2024-03-11

Family

ID=68728312

Family Applications (1)

Application Number Title Priority Date Filing Date
PT207997958T PT4045038T (pt) 2019-10-18 2020-10-16 Novas formulações de 4-cloro-n-[2-[(4-clorofenil)metil]-3-oxo-1,2,4-tiadiazol-5-il]benzamida

Country Status (16)

Country Link
US (1) US20230096218A1 (enExample)
EP (2) EP4045038B1 (enExample)
JP (3) JP7554263B2 (enExample)
KR (1) KR20220084379A (enExample)
CN (2) CN119112886A (enExample)
AU (1) AU2020366142A1 (enExample)
CA (1) CA3154915A1 (enExample)
DK (1) DK4045038T3 (enExample)
ES (1) ES2977279T3 (enExample)
FI (1) FI4045038T3 (enExample)
GB (1) GB201915094D0 (enExample)
HU (1) HUE066075T2 (enExample)
MX (2) MX2022004615A (enExample)
PL (1) PL4045038T3 (enExample)
PT (1) PT4045038T (enExample)
WO (1) WO2021074646A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11691954B2 (en) 2019-10-18 2023-07-04 Betagenon Ab Formulations
GB202100352D0 (en) * 2021-01-12 2021-02-24 Balticgruppen Bio Ab New methods
WO2025017193A1 (en) * 2023-07-20 2025-01-23 Betagenon Ab Methods of treating cardiomyopathy induced by metabolic inflexibility
WO2025017194A1 (en) * 2023-07-20 2025-01-23 Betagenon Ab Methods for regulating blood glucose levels using a dual ampk activator and mitochondrial uncoupler

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2166328B1 (es) 2000-05-11 2003-09-16 Consejo Superior Investigacion Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
WO2006045581A1 (en) 2004-10-21 2006-05-04 Neuropharma, S.A. The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators
UA94724C2 (en) * 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
JP5982281B2 (ja) 2009-07-08 2016-08-31 バルティック バイオ アーベー 医薬として有用な化合物
WO2013108026A1 (en) * 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
AU2018448511B2 (en) * 2018-11-05 2025-07-03 Betagenon Ab Methods of treating diabetes in severe insulin-resistant diabetic subjects

Also Published As

Publication number Publication date
CA3154915A1 (en) 2021-04-22
US20230096218A1 (en) 2023-03-30
HUE066075T2 (hu) 2024-07-28
EP4316470B1 (en) 2026-04-29
EP4045038A1 (en) 2022-08-24
JP7554263B2 (ja) 2024-09-19
CN114630824B (zh) 2024-09-24
EP4045038B1 (en) 2023-12-06
CN119112886A (zh) 2024-12-13
MX2025003950A (es) 2025-08-01
FI4045038T3 (fi) 2024-03-13
AU2020366142A1 (en) 2022-06-02
JP2022553268A (ja) 2022-12-22
PL4045038T3 (pl) 2024-06-24
WO2021074646A1 (en) 2021-04-22
MX2022004615A (es) 2022-07-11
JP2024174965A (ja) 2024-12-17
JP7771316B2 (ja) 2025-11-17
ES2977279T3 (es) 2024-08-21
CN114630824A (zh) 2022-06-14
GB201915094D0 (en) 2019-12-04
JP2026027357A (ja) 2026-02-18
KR20220084379A (ko) 2022-06-21
DK4045038T3 (en) 2024-03-18
EP4316470A3 (en) 2024-02-28
EP4316470A2 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
PT4045038T (pt) Novas formulações de 4-cloro-n-[2-[(4-clorofenil)metil]-3-oxo-1,2,4-tiadiazol-5-il]benzamida
EP3860449A4 (en) ELECTRODE ARRANGEMENT
EP3813634A4 (en) ARTICULATING MEDICAL INSTRUMENTS
MA53172A (fr) Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
MA53170A (fr) Composés de sulfonylurée en tant qu'inhibiteurs de l'activité de l'interleukine 1
MA50159A (fr) Nouvelles combinaisons stables de charpentes de domaines variables d'anticorps
JP1721421S (ja) ヘアーブラシのパドル形状部
EP4028059A4 (en) STABLE MEDICAL CANNABIDIOL COMPOSITIONS
EP3875542A4 (en) SILICONE EMULSION COMPOSITION
EP3814911A4 (en) Controlling nand operation latency
EP3785698A4 (en) EDARAVON PHARMACEUTICAL COMPOSITION
EP4161452C0 (en) ANKLE-FOOT PROSTHETIC DEVICE, IN PARTICULAR OF THE BIOMIMETIC TYPE
EP3761945A4 (en) PRESERVATION OF PERSONAL CARE COMPOSITIONS
EP3935037A4 (en) USE OF 8,9-DIHYDROCANNABIDIOL COMPOUNDS
EP3833342A4 (en) IMIDAZOTETRAZINE COMPOUNDS
MA53021A (fr) Composition de diacide oligosaccharidique d'alginate
EP3897660A4 (en) NEW CRYSTALLINE FORMS OF AN NRTTI COMPOUND
EP4003323A4 (en) STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES
EP4168401A4 (en) Sulphonamide compounds
EP3782212A4 (en) GENERATIVE MANUFACTURING USING ELECTROCHEMICALLY ACTIVE FORMULATIONS
EP3679016A4 (en) SOLID FORMS OF 2- (5- (4- (2-MORPHOLINOETHOXY) PHENYL) PYRIDINE-2-YL) -N-BENZYL ACETAMIDE
IL311341A (en) Improved perfume compositions comprising sulfur-containing pro-fragrance compounds
EP3445763A4 (en) Novel Crystalline Salt Forms of 3- (1,2,4-triazolo [4,3-A] pyridine-3-yl-ethyl-2-yl) -4-methyl-N- (4 - ((4-methylpiperazine-1-yl) methyl) - 3-trifluoromethylphenyl) BENZAMIDE FOR MEDICAL USE
EP3931252A4 (en) STARCH COMPOSITIONS
EP3965795A4 (en) STABLE ALBUVIRTID COMPOSITIONS